**Special Section on Transporters in Drug Disposition and Pharmacokinetic Prediction**

**Hepatic Transport of 25-Hydroxyvitamin D₃ Conjugates: A Mechanism of 25-Hydroxyvitamin D₃ Delivery to the Intestinal Tract**

Chunying Gao, Michael Z. Liao, Lyrialle W. Han, Kenneth E. Thummel, and Qingcheng Mao

Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington

Received October 9, 2017; accepted February 15, 2018

**ABSTRACT**

Vitamin D₃ is an important prohormone critical for maintaining calcium and phosphate homeostasis in the body and regulating drug-metabolizing enzymes and transporters. 25-Hydroxyvitamin D₃ (25OHD₃), the most abundant circulating metabolite of vitamin D₃, is further transformed to the biologically active metabolite 1α,25-dihydroxyvitamin D₃ (1α,25-(OH)₂D₃) by CYP27B1 in the kidney and extrarenal tissues, and to nonactive metabolites by other cytochrome P450 enzymes. In addition, 25OHD₃ undergoes sulfation and glucuronidation in the liver, forming two major conjugative metabolites, 25OHD₃-3-O-sulfate (25OHD₃-S) and 25OHD₃-3-0-glucuronide (25OHD₃-G), both of which were detected in human blood and bile. Considering that the conjugates excreted into the bile may be circulated to and reabsorbed from the intestinal lumen, deconjugated to 25OHD₃, and then converted to 1α,25-(OH)₂D₃, exerting local intestinal cellular effects, it is crucial to characterize enterohepatic transport mechanisms of 25OHD₃-S and 25OHD₃-G, and thereby understand and predict mechanisms of interindividual variability in mineral homeostasis. In the present study, with plasma membrane vesicle and cell-based transport studies, we showed that 25OHD₃-S is a substrate of multidrug resistance proteins 2 and 3, OATP1B1, and OATP1B3, and that 25OHD₃-G is probably a substrate of breast cancer resistance protein, OATP2B1, and OATP1B3. We also demonstrated sinusoidal and canalicular efflux of both conjugates using sandwich-cultured human hepatocytes. Given substantial expression of these transporters in liver hepatocytes and intestinal enterocytes, this study demonstrates for the first time that transporters could play important roles in the enterohepatic circulation of 25OHD₃ conjugates, providing an alternative pathway of 25OHD₃ delivery to the intestinal tract, which could be critical for vitamin D receptor-dependent gene regulation in enterocytes.

**Introduction**

Vitamin D₃ is essential for regulation of calcium and phosphate homeostasis in the body. Vitamin D₃ exerts most of its biologic functions through a biologically active metabolite, 1α,25-dihydroxyvitamin D₃ (1α,25-(OH)₂D₃), which binds with high affinity to vitamin D receptor (VDR) and activates transcription of target genes (Christakos, 2012). Besides regulating intestinal absorption of calcium and phosphate, VDR signaling also appears to be important for regulation of human intestinal CYP3A4 expression (Thummel et al., 2001), which has been shown to be associated with seasonal changes in vitamin D production (Thunmaran et al., 2012) and can be modified by vitamin D supplementation (Schwartz, 2009).

The biologically active metabolite 1α,25-(OH)₂D₃ is generated following two metabolic steps (Fig. 1). First, 25-hydroxyvitamin D₃ (25OHD₃) is produced from vitamin D₃ primarily by hepatic CYP2R1. 25OHD₃, which is the major circulating form of vitamin D₃ (Henry and Norman, 1984), tightly binds to plasma proteins (e.g., vitamin D-binding protein, DBP) and exhibits a relatively long (~14 days) plasma half-life, and therefore is used as a biomarker for vitamin D exposure (Holick, 2007). 25OHD₃ is then further metabolized to 1α,25-(OH)₂D₃ primarily by CYP27B1 in the kidney and certain extrarenal tissues (Hewison et al., 2007; Feldman et al., 2014).

Although the kidney is generally regarded to be the main source of 1α,25-(OH)₂D₃, CYP27B1 is also expressed in a number of extrarenal tissues, including intestinal epithelial cells (Bikle, 2009, 2014). Importantly, as suggested by Balesaria et al. (2009) and others (Bises et al., 2004), 1α,25-(OH)₂D₃-mediated biologic effects in the intestine might also be produced via an intracellular process involving the bioactivation of 25OHD₃ by intestinal CYP27B1. A recent study provided direct experimental evidence that CYP27B1 in duodenum indeed can metabolize 25OHD₃ and contribute to local 1α,25-(OH)₂D₃ production in the intestine (Gawlik et al., 2015). However, the delivery of 25OHD₃ to the intestinal mucosal cells remains unclear but could involve production and delivery of vitamin D₃ conjugates.
Studies in humans using radioactive compounds suggested that vitamin D$_3$ and its hydroxylated metabolites are excreted through the bile in the forms of conjugates (Avioli et al., 1967). In one study, it was suggested that 25OHD$_3$ undergoes extensive enterohepatic circulation, where 85% of secreted radioactivity into duodenum was reabsorbed in 24 hours after intravenous administration of [3H]-25OHD$_3$ (Arnaud et al., 1975). Considering the wide distribution of β-glucuronidase (Whiting et al., 1993; Oleson and Court, 2008) and steroid sulfatase (Miki et al., 2002) in intestinal bacteria and within the enterocyte, conjugated 25OHD$_3$ in the bile may be reabsorbed from the intestinal lumen in an intact form or as an aglycone after hydrolysis by enzymes or bacteria in the intestinal tract.

In addition to 1α-hydroxylation, 25OHD$_3$ undergoes a series of catabolic hydroxylation reactions (e.g., 23S, 24R, and 4β) that mediate inactivation of vitamin D$_3$ and its excretion (Christakos et al., 2010; Wang et al., 2012). 25OHD$_3$ also undergoes sulfation and glucuronidation in the liver, generating two major circulating conjugative metabolites, 25OHD$_3$-3-O-sulfate (25OHD$_3$-S) (Wong et al., 2018) and 25OHD$_3$-3-O-glucuronide (25OHD$_3$-G) (Wang et al., 2014) (Fig. 1). In healthy humans, plasma concentrations can reach as high as 185 nM for 25OHD$_3$, 100 nM for 25OHD$_3$-S, and 10 nM for 25OHD$_3$-G (Gao et al., 2017). Both conjugative metabolites are tightly bound to DBP, with an affinity similar to that of 25OHD$_3$, and were not detected in the urine of healthy individuals. The high protein binding of vitamin D$_3$ conjugates in the blood not only reduces urinary excretion from the body but also greatly limits the passive diffusion and active transport across membrane barriers and thus minimizes the delivery of unbound vitamin D$_3$ conjugates to target tissues (e.g., intestinal epithelia) in the body. In contrast, owing to the absence of binding proteins in the bile, biliary conjugates of vitamin D$_3$ should be directly accessible to the intestinal epithelia cells and uptake transporters for hormone conjugates (Hofmann, 2011). We hypothesized that 25OHD$_3$ conjugates excreted into the bile are deconjugated by bacterial or intracellular sulfatase and glucuronidase and then hydroxylated by intestinal CYP27B1 to 1α,25-(OH)$_2$D$_3$, thereby regulating VDR target gene expression.

To test the hypothesis that the regulation of intestinal VDR target genes is mediated in part by 1α,25-(OH)$_2$D$_3$ in the intestinal tract, it is essential to understand the hepatic and intestinal transport of conjugative 25OHD$_3$ metabolites. However, to date, there is essentially nothing known about these processes. The objective of the current study was to characterize the major uptake and efflux transport mechanisms for 25OHD$_3$-S and 25OHD$_3$-G in the liver.

Fig. 1. Major metabolic pathways of vitamin D$_3$ in humans.
Materials and Methods

Materials. Ko143, MK571, indomethacin, rifampin, cyclosporine A (CsA), fumitremorgin C, cholic acid, taurocholate, estrone-3-sulfate (E1-3-S), estradiol-17β-glucuronide (E2-17β-G), estradiol-3-sulfate (E2-3-S), 3′-phosphoadenosine-5′-phosphosulfate, ATP disodium salt, adenosine 5′-monophosphate (AMP) monohydrate, and glutathione were purchased from Sigma-Aldrich (St. Louis, MO). 25OHD₃, d₂-25OHD₃, 25OHD₃-S, and 25OHD₃-G were obtained from Toronto Research Chemicals (Toronto, Canada). Hygromycin B, G-418, and RIPA lysis buffer were purchased from (Thermo Fisher Scientific, Waltham, MA). All other buffers and chemicals were of the highest grade commercially available.

Cell culture medium, antibiotic-antimycotic solution (100 l units/ml penicillin, 100 l units/ml streptomycin, 0.25 l units/ml amphotericin B, and 400 l units/ml hygromycin B. CHO cells stably expressing OATP1B1 (CHO/OATP1B1) and OATP1B3 (CHO/OATP1B3) were cultured in media without Na-butyrate for 48 hours straight. Prior to uptake assay, cells were grown under the same conditions were lysed with 0.25 ml of RIPA cell lysis buffer (Beyotime, Beijing, China) and subjected to solid-phase extraction (SPE) using Waters Oasis WAX (60 mg, 3 cc) anion exchange cartridges. Eluates from the SPE columns were then dried and reconstituted in 10 μl of methanol and derivatized with 4-(dimethylamino phenyl)-1,2,4-triazoline-3,5-dione (DAPTAD) for 1 hour at room temperature in the dark. The reaction mixture was evaporated under N₂ flow and reconstituted in 100 μl of mobile phase. A centrifugation step (13,362 g, for 5 minutes) was applied to remove insoluble materials prior to LC-MS/MS analysis. DAPTAD-25OHD₃-S, DAPTAD-d₂-25OHD₃-S, DAPTAD-25OHD₃-G, and DAPTAD-d₂-25OHD₃-G were analyzed using an AB Sciex QTRAP 6500 LC-MS/MS system. Owing to the lack of blank bile sample, calibration curves were plotted with corrected peak area ratios of DAPTAD-25OHD₃-S/G and DAPTAD-d₂-25OHD₃-S/G by subtracting “blank” samples from those spiked with serial 25OHD₃-S and 25OHD₃-G solutions.

Inside-Out Membrane Vesicular Uptake Assay. A rapid filtration technique modified from a previously reported method (Gao et al., 2012a) was used for inside-out plasma membrane vesicular transport assays. In brief, plasma membrane vesicles (25 μg protein) and test compounds of various concentrations were incubated at 37°C in the presence of ATP or AMP (5 mM) in a buffer (pH 7.0) containing 10 mM Tris/HCl, 10 mM MgCl₂, and 250 mM sucrose for 90 minutes without centrifugation. After incubation, the mixture was centrifuged at 435,000 g for 9 minutes using a Sorvall Discovery M150 SE ultracentrifuge (Thermo Fisher Scientific) and a Thermo Fisher Scientific S100-AT3 rotor. The supernatant (100 μl) was transferred to a 96-well plate and then washed five times with 100 μl of ice-cold buffer (containing 1.5% BSA for 25OHD₃-S and 25OHD₃-G). The cell pellets were reconstituted in 100 μl of mobile phase for LC-MS analysis. In parallel, cells were laced with 0.25 ml of methanol containing corresponding internal standard and centrifuged at 13,362 g for 5 minutes. The supernatant was then evaporated and reconstituted in 100 μl of mobile phase. A centrifugation step (13,362 g, for 5 minutes) was applied to remove insoluble materials prior to LC-MS/MS analysis. DAPTAD-25OHD₃-S, DAPTAD-d₂-25OHD₃-S, DAPTAD-25OHD₃-G, and DAPTAD-d₂-25OHD₃-G were analyzed using an AB Sciex QTRAP 6500 LC-MS/MS system. Owing to the lack of blank bile sample, calibration curves were plotted with corrected peak area ratios of DAPTAD-25OHD₃-S/G and DAPTAD-d₂-25OHD₃-S/G by subtracting “blank” samples from those spiked with serial 25OHD₃-S and 25OHD₃-G solutions.

Data Analysis for Uptake Assays. All the membrane vesicular and cellular uptake experiments were performed in triplicate or quadruplicate with at least two independent repeats. Differences in membrane vesicular uptake between ATM and AMP or in cellular accumulation between organic anion transporting polypeptide (OATP)-expressing and control cells were analyzed using unpaired Student’s t test. Differences with P value of <0.05 were considered statistically significant.
significant. $K_a$ and $V_{\text{max}}$ of transport kinetics were estimated by fitting of experimental data to the Michaelis-Menten equation with nonlinear regression. IC$_{50}$ values were also determined by nonlinear regression as previously described (Duan et al., 2015). All the analyses were performed using the GraphPad Prism software (vers. 5.01; La Jolla, CA).

Efflux of 25OHD$_3$-S or 25OHD$_3$-G from Sandwich-Cultured Human Hepatocytes. SCHHs were obtained from five female donors (HH1053, HH1065, HH1007, and HH1103) and one male donor (HH1031). SCHHs were plated in 96-well plates on day 1 by the vendor and shipped with 37°C heating patches overnight on day 2. Upon arrival of cells, the culture media was replaced with fresh and warm hepatocyte maintenance media provided by the vendor and the cells were cultured for another 2 days with medium change every day. On day 5, cells were washed and precultured in HBSS with 25OHD$_3$, at 10 μM for 4 hours and efflux was initiated by washing and incubating cells with 100 μl of fresh HBSS buffer with or without calcium. Human vitamin D-binding protein was added to incubation buffer to 3 μM concentration during the efflux phase to reduce nonspecific binding of 25OHD$_3$ conjugates (e.g., to cell membrane and plastic cell culture flask). To confirm if efflux transporters are involved in the canalicular and sinusoidal efflux of 25OHD$_3$-S and 25OHD$_3$-G, the BCRP inhibitor fumitremorin C (FTC) (10 μM) or the MRP inhibitor MK571 (40 μM) was added to the incubation buffer throughout the 4-hour loading and 20-minute efflux phases. As a positive control, SCHHs were loaded with 100 μM taurocholate for 20 minutes, and the efflux was initiated by washing and incubating the cells with fresh HBSS with or without calcium. During the efflux phase, incubation buffer (100 μl) was collected at designated time points from corresponding wells that were loaded with 25OHD$_3$ or taurocholate. The cells were lysed with 100 μl methanol and collected at the end of the efflux phase. For 25OHD$_3$-G group, collected incubation buffers and cell lysates were spiked with deuterated internal standards d$_4$-25OHD$_3$-S and d$_5$-25OHD$_3$-G and evaporated to dryness before being derivatized with DAPTAD. For the taurocholate group, incubation buffers were spiked with internal standard cholic acid and evaporated to dryness before being reconstituted in 100 μl of mobile phase. The resulting samples were subject to quantification by LC-MS/MS as described below.

In the presence of calcium, the tight junctions between hepatocytes and the canalicular networks remain intact, allowing movement of efflux across the sinusoidal membrane of hepatocytes. Removal of calcium from the incubation buffer disrupts the tight junctions and allows measurement of efflux across both the canalicular and sinusoidal membranes. Therefore, the difference in efflux between the with- and without-calcium samples represents biliary efflux of a test compound. Biliary efflux index (BEI) was calculated using the equation: BEI (%) = [(Efflux (sinusoidal + canalicular) – Efflux (sinusoidal))/Efflux (sinusoidal + canalicular)] × 100.

Analytical Methods. Given the simple matrix and relatively high concentrations, 25OHD$_3$-S and 25OHD$_3$-G in vesicular and cellular uptake, as well as the unbound fraction-determination assays, were quantified using a straightforward LC-MS method reported by Wang et al. (2014). As for experiments with SCHHs, owing to low production of 25OHD$_3$-S and 25OHD$_3$-G in hepatocytes, 25OHD$_3$-S and 25OHD$_3$-G in the incubation buffers and cell lysates were derivatized with DAPTAD and quantified using a sensitive LC-MS/MS method as previously described (Gao et al., 2017).

E2-17β-G in the membrane vesicular and cellular uptake assays was quantified using LC-MS with E2-3-S as the internal standard. Briefly, chromatographic separation was achieved on a Waters Symmetry C18 (2.1 × 50 mm, 3.5 μm) column (Waters, Milford, MA) with a mobile phase consisting of 1 mM ammonium chloride (A) and methanol (B) at 45°C. A linear gradient from 20% B (0–0.5 minutes) to 75% B (4 to 5 minutes) in 3.5 minutes at a 0.25 ml/min flow rate was employed. The mass spectrometer was operated in the negative ionization mode. E2-17β-G and E2-3-S were detected by selective ion monitoring at m/z 447 and m/z 351, respectively.

E2-3-S in the OATP2B1-overexpressing cell uptake assay was quantified using LC-MS with E2-3-S as the internal standard. Chromatographic separation was achieved using a Waters Symmetry C18 (2.1 × 50 mm, 3.5 μm) column on an Agilent 1200 LC system. The elution was performed at a flow rate of 0.25 ml/min with the mobile phase containing 0.1% formic acid in water and methanol at a ratio of 30:70 (v/v). Mass spectrometric analysis was carried out using a negative mode electrospray ionization method on an Agilent 6410 triple quadrupole tandem mass spectrometer. Single-ion monitoring at m/z 351 and m/z 349 was applied for detection of E2-3-S and E2-3-S, respectively.

Results

Human Bile Analysis. To confirm the presence of 25OHD$_3$-S and 25OHD$_3$-G in human bile, pooled healthy human bile was derivatized with DAPTAD and analyzed using a sensitive LC-MS/MS method we developed (Gao et al., 2017). As shown in Fig. 2, peaks were observed in bile for both DAPTAD-25OHD$_3$-S (Fig. 2A) and DAPTAD-25OHD$_3$-G (Fig. 2C) at the expected slightly longer retention times shown by their corresponding deuterated internal standards (Fig. 2, B and D). On the basis of the calibration curves established with 25OHD$_3$-S and 25OHD$_3$-G standards, concentrations of 25OHD$_3$-S and 25OHD$_3$-G in the pooled human bile were estimated to be around 2.55 and 0.30 nM, respectively.

ATP-Dependent Uptake of 25OHD$_3$-G into Inside-Out Plasma Membrane Vesicles. Detection of 25OHD$_3$-S and 25OHD$_3$-G in human bile suggests that these conjugates are probably formed in the liver and subsequently transported to the bile via efflux transporters on the canalicular membrane of the hepatocytes. To test this possibility, we first performed a rapid screening of hepatic efflux transporters for 25OHD$_3$-S and 25OHD$_3$-G using plasma membrane vesicle transport assays. Major hepatic efflux transporters frequently reported to be involved in the efflux transport of conjugative metabolites were screened using transporter-overexpressing plasma membrane vesicles; these included MRP2 and BCRP on the hepatic canalicular membrane and MRP3 and MRP4 on the sinusoidal membrane. Statistically significant differences in uptake of 50 μM E2-17β-G, a known substrate of these transporters, into plasma membrane vesicles between the ATP and AMP groups were observed with vesicles overexpressing each of the transporters (Fig. 3A). Differences between the ATP and AMP groups associated with the mock control vesicles were also significant but much smaller than those associated with the transporter-overexpressing vesicles. Furthermore, uptake of E2-17β-G into transporter-overexpression vesicles was significantly greater than that into the mock control vesicles in the presence of ATP (Fig. 3A). These data confirmed that the membrane vesicles we used were functional. By incubating 2 μM of 25OHD$_3$-G with membrane vesicles at 37°C for 5 minutes, significant ATP-dependent active uptake of 25OHD$_3$-G by MRP2 and MRP3 was observed (Fig. 3B), suggesting that 25OHD$_3$-G is a substrate of these efflux transporters. On the other hand, there was no significant active uptake of 25OHD$_3$-G by BCRP and MRP4 (Fig. 3B), suggesting that 25OHD$_3$-G is not a substrate of BCRP and MRP4. To further confirm these findings, we performed inhibition studies using selective MRP inhibitors. MK571 (Weiss et al., 2007) and indomethacin (Draper et al., 1997) are relatively selective inhibitors for MRP transporters. We found that the net ATP-dependent uptake of 25OHD$_3$-G at 2 μM into MRP2- and MRP3-expressing plasma membrane vesicles was significantly reduced by 50 μM MK571 to 70% (Fig. 4A) and 50% (Fig. 4B), respectively. Indomethacin at 672 μM also significantly inhibited MRP3-mediated active uptake of Taurocholate in SCHH efflux experiments was quantified using cholic acid as the internal standard. Chromatographic separation was achieved using a Waters Symmetry C18 (2.1 × 50 mm, 3.5 μm) column on an Agilent 1200 LC system. The elution was performed at a flow rate of 0.25 ml/min with the mobile phase containing acetonitrile and 10 mM ammonium acetate (native pH) at a ratio of 64:36 (v/v). Mass spectrometric analysis was carried out using a negative mode electrospray ionization method on an Agilent 6410 triple quadrupole tandem mass spectrometer. Single-ion monitoring at m/z 514 and m/z 407 was applied for detection of taurocholate and cholic acid, respectively.

The LC-MS quantification methods for E2-17β-G, E2-3-S and taurocholate were developed in-house; a linear standard curve ($r^2 > 0.99$) was established for each analytical batch, and the accuracy of interday and intraday quality control samples was within the range of 85%–115% during the analysis.
25OHD$_3$-G by ~75% (Fig. 4B). Results of the inhibition studies provided additional evidence to support the notion that 25OHD$_3$-G can be actively transported by MRP2 and MRP3. Both MK571 and indomethacin also decreased the net active uptake of 25OHD$_3$-G into Sf9 mock membrane vesicles (Fig. 4, A and B), suggesting that Sf9 cells express low levels of endogenous MRP transporters capable of transporting 25OHD$_3$-G.

We next estimated kinetic parameters ($K_m$ and $V_{max}$) for MRP2- and MRP3-mediated efflux of 25OHD$_3$-G. The representative transport kinetic profiles are shown in Fig. 4C for MRP2, and in Fig. 4D for MRP3. Given high nonspecific binding of 25OHD$_3$-G that can influence kinetic parameter estimation, we first determined unbound fractions of 25OHD$_3$-G in incubation buffers used in the vesicular transport assays, and then used unbound fractions to correct $K_m$ values. We found that the unbound fraction $Y$ (%) of 25OHD$_3$-G exhibited a linear relation with the total concentration $X$ following the equation: $Y = 0.0018X + 7.3119$ ($r^2 = 0.9965$) within the concentration range of $0$–$10$ µM, and then reached saturation at ~25%. After correction with unbound
fractions at respective total concentrations, the $K_m$ values for MRP2- and MRP3-mediated transport of 25OHD3-G were 1.56 ± 0.43 and 0.25 ± 0.04 μM, and the $V_{\text{max}}$ were 295.6 ± 87.1 and 66.7 ± 11.6 pmol/mg protein per minute, respectively.

Inhibition of Efflux Transporter Activity by 25OHD3-S. Owing to high nonspecific binding and passive diffusion, we noticed very high background levels associated with membrane vesicles even after extensive washing with 1.5% BSA or DBP. Such a high background appeared to completely mask activity of efflux transporters for 25OHD3-S with no significant differences in the uptake into membrane vesicles between the ATP and AMP groups (data not shown). Therefore, we were unable to demonstrate whether 25OHD3-S is a substrate of the efflux transporters examined, including BCRP, MRP2, MRP3, and MRP4. To further evaluate the interactions of 25OHD3-S with these transporters, inhibition studies using a model substrate of these transporters (E2-17β-G) were conducted. As shown in Fig. 5, 25OHD3-S effectively inhibited ATP-dependent transport of E2-17β-G by BCRP (Fig. 5A), MRP4 (Fig. 5B), and MRP3 (Fig. 5C) in a concentration-dependent manner, suggesting that 25OHD3-S is a ligand and possibly a substrate of these three transporter proteins. In contrast, 25OHD3-S did not inhibit MRP2-mediated transport of E2-17β-G at all (data not shown). We also determined unbound factions of

Fig. 4. ATP-dependent uptake of 25OHD3-G into Sf9 insect cell plasma membrane vesicles overexpressing MRP2 and MRP3. (A) 25OHD3-G at 10 μM was incubated with MRP2-overexpressing Sf9 plasma membrane vesicles or mock control membrane vesicles in the presence or absence of 50 μM MK571 at 37°C for 5 minutes. (B) 25OHD3-G at 3 μM was incubated with MRP3-overexpressing Sf9 plasma membrane vesicles or mock control membrane vesicles in the presence or absence of 50 μM MK571 or 672 μM indomethacin at 37°C for 5 minutes. Differences between the ATP and AMP groups (net ATP-dependent uptake) were calculated and compared between the MK571 or indomethacin and vehicle (dimethyl sulfoxide) treatments for statistical significance by Student’s t test. Data shown are means ± S.D. of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001, respectively. Representative kinetic profiles of MRP2- and MRP3-mediated ATP-dependent uptake of 25OHD3-G into Sf9 plasma membrane vesicles are shown in (C) and (D), respectively. 25OHD3-G of varying concentrations was incubated with membrane vesicles in the presence of ATP or AMP at 37°C for 5 minutes. The ATP-dependent net uptake into membrane vesicles was plotted against unbound concentrations of 25OHD3-G in the incubations. Data shown are means ± S.D. of three independent experiments each with triplicate determinations.

Fig. 5. 25OHD3-S inhibits ATP-dependent uptake of E2-17β-G into plasma membrane vesicles overexpressing BCRP, MRP4, and MRP3. Representative inhibition profiles of 25OHD3-S for ATP-dependent uptake of E2-17β-G into plasma membrane vesicles overexpressing BCRP (A), MRP4 (B), and MRP3 (C) that were incubated with 25OHD3-S and E2-17β-G at 37°C for 5 minutes. In the incubation, E2-17β-G was at 2 μM for MRP3 and 10 μM for BCRP and MRP4. ATP-dependent net uptake of E2-17β-G (differences between the ATP and AMP groups) was plotted against log10 values of unbound concentrations of 25OHD3-S in membrane vesicle incubations. Data shown are means ± S.D. of triplicate determinations in a single experiment. Unbound IC50 values were estimated from two independent experiments with triplicate determinations in each experiment.
25OHD$_3$-S in incubation buffers of the vesicular transport assays and found that the unbound fraction of 25OHD$_3$-S was $\sim$8% in both HEK293 and Sf9 membrane vesicles and independent of total concentration. After correction for unbound fraction, IC$_{50}$ values of 25OHD$_3$-S for inhibition of BCRP-, MRP4-, and MRP3-mediated transport of E$_2$-17$\beta$-G from duplicate experiments were estimated to be 1.0, 0.96, and 1.88 $\mu$M, respectively.

Efflux of 25OHD$_3$-S and 25OHD$_3$-G from Sandwich-Cultured Human Hepatocytes. According to results of membrane vesicular transport studies and the detection of 25OHD$_3$ conjugative metabolites in human bile as described above, we hypothesized that 25OHD$_3$-S and 25OHD$_3$-G are transported out of human hepatocytes into the bile after they are converted from 25OHD$_3$ in the liver. To test this hypothesis, we examined biliary efflux of 25OHD$_3$-S and 25OHD$_3$-G using SCHHs. Taurocholate is known to have extensive biliary efflux and therefore was used as a positive control for each preparation of SCHHs. As expected, the efflux of taurocholate from SCHHs in the absence of calcium was significantly higher than in the presence of calcium over time for all five different batches of SCHHs we used with the exception of HH1007 at earlier time points.

**Fig. 6.** Efflux of 25OHD$_3$-S, 25OHD$_3$-G, and taurocholate from SCHHs. SCHHs from five different donors (HH1055, HH1103, HH1031, HH1085, and HH1007) were incubated at 37°C with 10 $\mu$M 25OHD$_3$ for 4 hours or 2 $\mu$M taurocholate for 20 minutes. Efflux of 25OHD$_3$-S (A), 25OHD$_3$-G (B), or taurocholate (C) was then initiated by replacing culture media with Ca$^{2+}$-containing (sinusoidal efflux, filled circles) or Ca$^{2+}$-free (sinusoidal + canalicular efflux, open circles) HBSS. Human vitamin D-binding protein (3 $\mu$M) was added to the incubation buffer during the efflux phase. Data shown are means ± S.D. for quadruplicate determinations in a single experiment. Differences between with- (filled circles) and without- (open circles) calcium, which represent the canalicular efflux, were analyzed by Student’s t test. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$, respectively.
A dose of 25OHD$_3$ were formed with a product-formation ratio of around 30:1 (25OHD$_3$-S/25OHD$_3$-G), calculated on the basis of their recovery from efflux incubation buffers and cell lysates of SCHH. Both 25OHD$_3$-S and 25OHD$_3$-G rapidly appeared in the efflux buffer in the absence and presence of calcium and their concentrations increased with time, suggesting a time-dependent passive or active efflux of the conjugates from hepatocytes (Fig. 6). We noticed substantial interindividual variations in both sinusoidal and canalicular efflux of 25OHD$_3$-S and 25OHD$_3$-G among SCHHs from five different donors. The increases in concentrations of 25OHD$_3$-S and 25OHD$_3$-G in efflux buffers over time (0–20 minutes) in the presence of calcium, which represent sinusoidal efflux rates, followed the rank orders of HH1007 > HH1055 > HH1031 > HH1103 > HH1007 > HH1103 > HH1031 > HH1085 for 25OHD$_3$-S and 25OHD$_3$-G, respectively. In the absence of calcium, concentrations of 25OHD$_3$-S in efflux buffers over time were significantly higher than those in the presence of calcium in SCHHs from donors HH1055, HH1103, HH1085, and HH1007, but not HH1031. In particular, SCHHs from the donor HH1055 showed significantly higher canalicular efflux activity of 25OHD$_3$-S than other donors. Likewise, concentrations of 25OHD$_3$-G in efflux buffers over time in the absence of calcium were significantly higher than those in the presence of calcium in SCHHs from donors HH1055, HH1085 and HH1007 but not HH1031. The donor HH1031 did not exhibit canalicular efflux of either 25OHD$_3$-S nor 25OHD$_3$-G, despite high canalicular efflux of taurocholate.

To confirm if BCRP or MRPs are involved in the canalicular and sinusoidal efflux of 25OHD$_3$-S and 25OHD$_3$-G, FTC, a selective BCRP inhibitor, or MK571, a selective MRP inhibitor, was added to incubation buffer during the loading and efflux phases. SCHHs from the donor HH1055, which showed the highest efflux activity among all the donors analyzed, were used in the inhibition studies. As expected, the canalicular efflux of 25OHD$_3$-S was significantly decreased by the addition to FTC compared with control with no FTC added. We calculated biliary efflux index in the presence and absence of FTC. The mean BEI (%) of 25OHD$_3$-S from three independent experiments was significantly decreased by FTC at 15 and 20 minutes of efflux (Table 1), confirming that the biliary efflux of 25OHD$_3$-S is probably mediated by BCRP. However, the effects of MK571 on the efflux of 25OHD$_3$-G and 25OHD$_3$-S cannot be analyzed. Owing to the near complete inhibition by MK571 (data not shown), the two conjugative metabolites were undetectable in most of the efflux buffers analyzed.

**TABLE 1**

Biliary excretion index of 25OHD$_3$-S in SCHH in the presence and absence of the BCRP inhibitor FTC

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>BEI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>10</td>
<td>18.3 ± 12.4</td>
</tr>
<tr>
<td>15</td>
<td>30.8 ± 12.2</td>
</tr>
<tr>
<td>20</td>
<td>27.6 ± 7.3</td>
</tr>
</tbody>
</table>

*Differences with *P* values of <0.05 that were considered statistically significant.

**Cellular Uptake of 25OHD$_3$-G and 25OHD$_3$-S by OATPs.** OATP2B1 is a major uptake transporter in enterocytes and facilitates in intestinal absorption of xenobiotics (Tamai, 2012). Once in the bile, 25OHD$_3$-G and 25OHD$_3$-S could be excreted to the intestinal lumen and be absorbed into the enteroocytes by uptake transporters. In addition, 25OHD$_3$-G and 25OHD$_3$-S in the circulation may be transported back into the hepatocytes by uptake transporters on the sinusoidal membrane, such as OATP1B1 and OATP1B3. We therefore performed cellular uptake studies to show if 25OHD$_3$-G and 25OHD$_3$-S are substrates of OATP2B1, OATP1B1, and OATP1B3. E$_1$-3-S was used as a positive control, as it is a known substrate of OATP2B1. As expected, cellular accumulation of E$_1$-3-S in Flp-In-CHO/OATP2B1 cells was approximately 10 times greater than that in mock CHO control cells (Fig. 7A). We found that cellular accumulation of 25OHD$_3$-S in Flp-In-CHO/OATP2B1 cells was significantly increased by ~50% compared with that in mock CHO cells (Fig. 7A); however, there were no significant differences in uptake of 25OHD$_3$-G into OATP2B1 cells and the mock control cells (Fig. 7A). The results indicate that 25OHD$_3$-S, but not 25OHD$_3$-G, is a substrate of OATP2B1. Further kinetic measurements revealed an unbound k$_{\text{in}}$ of 1.9 ± 0.9 µM and a V$_{\text{max}}$ of 81.3 ± 11.8 pmol/mg protein per minute for OATP2B1-mediated uptake of 25OHD$_3$-S from five independent experiments. A representative kinetic profile of OATP2B1-mediated uptake of 25OHD$_3$-S is shown in Fig. 7B.

Furthermore, cellular accumulation of 25OHD$_3$-S in OATP1B3-overexpressing CHO cells was about 2-fold ($P < 0.001$) that in wild-type CHO parent cells and this difference was completely abolished by the addition of 20 µM CsA, a potent OATP inhibitor (Fig. 8A). On the other hand, there were no differences in cellular accumulation of 25OHD$_3$-S in OATP1B1-overexpressing cells and the wild-type CHO parent cells (Fig. 8A). The data indicate that 25OHD$_3$-S is a substrate of OATP1B3, but not OATP1B1. Likewise, cellular accumulation of 25OHD$_3$-G in OATP1B1- and OATP1B3-overexpressing cells was approximately 4-fold ($P < 0.001$) and 25-fold ($P < 0.001$) greater than that in the wild-type CHO parent cells, respectively, and this difference was completely diminished by CsA (Fig. 8B). Therefore, 25OHD$_3$-G is a substrate of both OATP1B1 and OATP1B3.

**Discussion**

The present study demonstrates active transport of 25OHD$_3$-S and/or 25OHD$_3$-G by MRPs, BCRP, OATP1B1, OATP1B3, or OATP2B1. Owing to the lipophilic side chain at carbon C20, 25OHD$_3$-S and 25OHD$_3$-G were highly bound to cell membrane and plastic surface. This resulted in high background levels in membrane vesicular and cellular accumulation assays that masked real active transport, and initially no direct uptake could be observed for either 25OHD$_3$-S or 25OHD$_3$-G on our first try. To reduce nonspecific binding, we optimized washing steps with a final washing buffer containing 1.5% BSA (w/v) that were repeated five and two times for membrane vesicle and intact cell, respectively. Addition of DBP offered no further advantage (data not shown). These conditions allowed us to quantify direct active uptake of 25OHD$_3$-G into membrane vesicles and transfected cells, and active uptake of 25OHD$_3$-S into transfected cells, but not membrane vesicles. Although we did not observe ATP-dependent transport of 25OHD$_3$-S into membrane vesicles, we found that 25OHD$_3$-S was a potent inhibitor of E$_2$-17β-G transport by BCRP, MRPs, and MRP4, indicating that 25OHD$_3$-S is a ligand and possibly a substrate of these transporters.

Dehydroepiandrosterone sulfate (DHEAS) is a steroid sulfate conjugate with a structure similar to 25OHD$_3$-S, except for the lipophilic side.
chain at carbon C20. DHEAS has been shown to be a potent inhibitor of MRP1, MRP4, and BCRP, and a substrate of these transporters by direct vesicular uptake (Suzuki et al., 2003; Zelcer et al., 2003). Considering the similar structures of 25OHD3-S and DHEAS, it is plausible that they share comparable transporter-binding properties. Therefore, inhibition of transporter activities by 25OHD3-S, which was observed in the current study, is most probably competitive in nature, and 25OHD3-S is possibly a substrate of MRP3, MRP4, and BCRP. Whether active transport of 25OHD3-S is of physiologic importance depends on the extent of passive diffusion versus nonspecific sequestration in the membrane vesicle systems, something we have not been able to address at this time. The failure to show direct uptake of 25OHD3-S into membrane vesicles could have been the result of high membrane permeability driven by high lipophilicity [LogP: 7.386, calculated using ACD/Labs Software V11.02 (Toronto, ON, Canada)] compared with DHEAS (LogP: 3.522), much smaller inner space volume of membrane vesicles compared with intact cells, as well as high levels of protein binding. These resulted in high background levels associated with membrane vesicles that could not be reduced by extensive wash with high concentrations of BSA and DBP.

To confirm biliary transport in a more physiologic model, efflux of 25OHD3-S and 25OHD3-G were investigated in SCHHs. There are theoretically two ways to load the compounds in this system: 1) directly load 25OHD3-S and 25OHD3-G and determine the efflux after removing excessive free compounds and 2) incubate 25OHD3 with SCHHs to generate 25OHD3-S and 25OHD3-G, and then observe the efflux of produced metabolites. Direct loading appears to be straightforward, time-saving, and not affected by metabolite formation activity of the hepatocyte. However, after several attempts, we found that excessive unbound conjugates from the loading step could not be sufficiently removed, even after extensive washing with BSA-containing media, to permit quantitation of net active transport. Therefore, the second method was adopted, and the conjugates were generated de novo from 25OHD3 in SCHHs before assessment of hepatic efflux. Of course, this had the advantage of better mimicking in vivo hepatic disposition of the 25OHD3 conjugates. We also found that it was necessary to include DPB in the efflux buffer to facilitate release of 25OHD3-S and 25OHD3-G from cell surfaces during the efflux phase, something that is also expected in vivo for basolateral transport. Without DBP, only minimal amount of 25OHD3-S and 25OHD3-G could be detected in the efflux buffer, which is consistent with the competing affinity of 25OHD3-S and 25OHD3-G for cell membranes or plastic surface. However, it is difficult to predict what happens during biliary transport on the basis of our in vitro observation. Bile does not contain DBP, but it
25OHD3-G, OATP1B1, OATP2B1, and OATP1B3 are the major transporters for 25OHD3-S from the liver. To inhibit MRPs, we used MK571, the most commonly used MRP inhibitor. However, we found that MK571 had a profound effect on the conjugative enzymes, essentially abolishing 25OHD3-S and 25OHD3-G formation from 25OHD3. This has also been observed by other researchers (Barrington et al., 2015). Owing to low metabolic formation, the roles of MRPs in the efflux of 25OHD3-S and 25OHD3-G in SCHHs could not be evaluated. We recognize that the concentration of 25OHD3 (10 μM) we used in experiments with SCHHs is not a physiologic exposure. Lower concentrations could not be used because of analytical limitations. However, given the very long half-life of 25OHD3 in humans (14 days), we would suggest that hepatic 25OHD3 conjugation and biliary secretion in vivo is a slow but physiologically important process, even at low (50 nM) physiologic concentrations of 25OHD3.

The absence of 25OHD3-S and 25OHD3-G in urine, despite significant circulating concentrations (Wong et al., 2018), suggests that there is an effective means for hepatic reuptake of 25OHD3-S and 25OHD3-G. OATP1B1, OATP2B1, and OATP1B3 are the major uptake transporters on the sinusoidal membrane of hepatocytes (Badée et al., 2015). Besides the liver, OATP2B1 is also expressed in many other tissues, including intestinal epithelial cells (Gröer et al., 2013). We showed that 25OHD3-S is a good substrate of OATP2B1 and OATP1B3, providing a mechanism for excretion from the body through the liver. This also offers a mechanism for intestinal absorption of 25OHD3-S, followed by excretion into the bile (by BCRP). Similarly, the excretion of 25OHD3-G from the body may be initiated by OATP1B1/OATP1B3-mediated hepatic uptake, followed by MRP2-mediated biliary excretion. Although 25OHD3-G was not transported by OATP2B1, it might be deconjugated by intestinal bacteria, which are rich in glucuronidase and can hydrolyze diverse types of glucuronide conjugates (Kim and Jin, 2001; Gao et al., 2011). Generated 25OHD3 could then be reabsorbed from the intestinal lumen by passive diffusion.

Considering that 25OHD3-S (Wong et al., 2018) and 25OHD3-G (Wang et al., 2014) are strongly bound to DBP and that DBP is produced in the liver, it is possible that the conjugates formed in the liver could also be effluxed into bile out of the liver bound to the DBP, following protein synthesis in the liver. This mechanism was postulated for other lipophilic vitamins, such as vitamin E (Drevon, 1991) and vitamin K (Shearer et al., 2012), which are transported out of the liver bound to lipoproteins. Whether this occurs for 25OHD3 conjugates is unknown and remains to be investigated.

In summary, as shown in Fig. 9, the present study revealed that 25OHD3-G is a substrate of MRP2, MRP3, OATP1B1, and OATP1B3, and that 25OHD3-S is a substrate of OATP2B1 and OATP1B3, and possibly a substrate of BCRP, MRP3, and MRP4. Thus, in the liver, 25OHD3-G and 25OHD3-S could be excreted into the bile though MRP2 and BCRP, respectively, and back into the blood circulation by MRP3 (both) and MRP4 (25OHD3-S). The sinusoidal OATP transporters may pump unbound 25OHD3-G and 25OHD3-S from the blood into hepatocytes for further biliary excretion or blood recirculation. In the intestinal tract, OATP2B1 may mediate transport of 25OHD3-S into proximal enterocytes, following biliary excretion. Parts of the model presented in Fig. 9 related to the intestinal disposition and downstream effects of 25OHD3-G and 25OHD3-S are speculative and not yet supported by experimental evidence. We present it to stimulate further research and hypothesis testing. For example, can 25OHD3-S and 25OHD3-G be deconjugated to 25OHD3 by intestinal sulfatases or glucuronidases? Would this occur in the lumen of the gastrointestinal tract or after transporter-mediated uptake into enterocytes? What is the kinetics of 25OHD3 metabolism to 1α,25-(OH)2D3 following biliary secretion of 25OHD3 conjugates? Lastly, the relative importance of the conjugative pathways versus the oxidation pathways (shown in Fig. 1) in the systemic clearance of 25OHD3 remains unclear, as is the contribution of enterohepatic circulation of the 25OHD3 conjugates to the overall disposition and biologic activity of vitamin D. These are important topics of future investigation and the present study represents the first step in addressing this knowledge gap.

Acknowledgments

We would like to thank Dr. Danny D. Shen and Brian R. Phillips in the Department of Pharmaceutics, University of Washington, Seattle, WA for sharing LC-MS instruments and assistance in the analytical method development. We also greatly thank Drs. Bruno Stieger and Bruno Hagenbuch for their generous gifts of cell lines.